Analyst Expectations for Recursion Pharmaceuticals's Future
Portfolio Pulse from Benzinga Insights
Analysts have provided bullish ratings for Recursion Pharmaceuticals (NASDAQ:RXRX) in the last quarter, with an average price target of $18.14, implying an upside from the current price of $11.23. The average price target has increased by 2.66% over the past month.
August 09, 2023 | 3:00 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Analysts have provided bullish ratings for Recursion Pharmaceuticals, implying a potential upside.
The bullish ratings from analysts indicate a positive outlook for Recursion Pharmaceuticals. The average price target suggests a potential upside from the current price, which could lead to an increase in the stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100